Search results
Showing 7996 to 8010 of 8908 results
This evidence summary has been withdrawn following the MHRA pregnancy-prevention advice issued for women and men taking mycophenolate.
November 2024: This evidence summary has been withdrawn because licensed products are now available.
This evidence summary has been updated and replaced by NICE guideline NG78.
This evidence summary has been updated and replaced by NICE guideline NG97.
Antimicrobial prescribing: nebulised liposomal amikacin (ES36)
This evidence summary has been withdrawn. An NHS England clinical commissioning policy on nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial pulmonary disease caused by mycobacterium avium complex is available.
This evidence summary has been updated and replaced by NICE antimicrobial health technology evaluation guidance on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.
Parkinson's disease with motor fluctuations: safinamide (ES6)
This evidence summary has been updated and replaced by NICE guideline NG71.
Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)
This evidence summary has been updated and replaced by NICE guideline NG71.
This advice has been updated and replaced by NICE guideline NG199.
This evidence summary has been updated and replaced by NICE advice ESNM26.
This evidence summary has been withdrawn because the product is no longer available in the UK.
Acute diarrhoea in children: racecadotril as an adjunct to oral rehydration (ESNM12)
This evidence summary has been withdrawn because the product is no longer available in the UK.
This evidence summary has been withdrawn as the licence of ingenol mebutate gel has been suspended.
This evidence summary has been replaced by ESNM48
Irritable bowel syndrome with constipation in adults: linaclotide (ESNM16)
This evidence summary has been updated and replaced by NICE guideline CG61.